Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
Get Alerts JNJ Hot Sheet
Price: $275.23 --0%
EPS Growth %: +3.6%
Financial Fact:
Research and development expense: 2.18B
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +3.6%
Financial Fact:
Research and development expense: 2.18B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.90, $0.04 better than the analyst estimate of $2.86. Revenue for the quarter came in at $25.31 billion versus the consensus estimate of $25.02 billion.
GUIDANCE:
Johnson & Johnson sees FY2026 EPS of $11.50-$11.65, versus the consensus of $11.58. Johnson & Johnson sees FY2026 revenue of $100.8-101.4 billion, versus the consensus of $101.06 billion.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verizon and Corning reach multi-billion fiber supply deal
- Shopify (SHOP) PT Raised to $180 at Piper Sandler
- StimCell Energetics hires Stonegate Capital Markets as advisor
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share